Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6cebcedce5-trace').style.display = (document.getElementById('cakeErr67f6cebcedce5-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f6cebcedce5-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6cebcedce5-code').style.display = (document.getElementById('cakeErr67f6cebcedce5-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6cebcedce5-context').style.display = (document.getElementById('cakeErr67f6cebcedce5-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f6cebcedce5-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f6cebcedce5-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 13535,
		&#039;title&#039; =&gt; &#039;AIDAN proposes another pricing model for essential drugs by Khomba Singh&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 13 March, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/aidan-proposes-another-pricing-model-for-essential-drugs/articleshow/12&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 13657,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 13535,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | AIDAN proposes another pricing model for essential drugs by Khomba Singh&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;



A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;





The proposal of the All India Drug Action Network (AIDAN) is...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 13535,
	&#039;title&#039; =&gt; &#039;AIDAN proposes another pricing model for essential drugs by Khomba Singh&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 13 March, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/aidan-proposes-another-pricing-model-for-essential-drugs/articleshow/12&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 13657,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 13535
$metaTitle = &#039;LATEST NEWS UPDATES | AIDAN proposes another pricing model for essential drugs by Khomba Singh&#039;
$metaKeywords = &#039;Health,medicines&#039;
$metaDesc = &#039;



A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;





The proposal of the All India Drug Action Network (AIDAN) is...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | AIDAN proposes another pricing model for essential drugs by Khomba Singh | Im4change.org</title>
    <meta name="description" content="



A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;





The proposal of the All India Drug Action Network (AIDAN) is..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>AIDAN proposes another pricing model for essential drugs by Khomba Singh</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify"><br /></div><div style="text-align: justify">A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The group had earlier proposed another pricing formula but it was rejected by the industry. &quot;We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry,&quot; said Mira Shiva, founder co-ordinator of AIDAN.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &quot;impractical and non-transparent&quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The group had earlier proposed another pricing formula but it was rejected by the industry. &quot;We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry,&quot; said Mira Shiva, founder co-ordinator of AIDAN.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &quot;impractical and non-transparent&quot;.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6cebcedce5-trace').style.display = (document.getElementById('cakeErr67f6cebcedce5-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f6cebcedce5-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6cebcedce5-code').style.display = (document.getElementById('cakeErr67f6cebcedce5-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6cebcedce5-context').style.display = (document.getElementById('cakeErr67f6cebcedce5-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f6cebcedce5-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f6cebcedce5-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 13535,
		&#039;title&#039; =&gt; &#039;AIDAN proposes another pricing model for essential drugs by Khomba Singh&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 13 March, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/aidan-proposes-another-pricing-model-for-essential-drugs/articleshow/12&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 13657,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 13535,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | AIDAN proposes another pricing model for essential drugs by Khomba Singh&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;



A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;





The proposal of the All India Drug Action Network (AIDAN) is...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 13535,
	&#039;title&#039; =&gt; &#039;AIDAN proposes another pricing model for essential drugs by Khomba Singh&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 13 March, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/aidan-proposes-another-pricing-model-for-essential-drugs/articleshow/12&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 13657,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 13535
$metaTitle = &#039;LATEST NEWS UPDATES | AIDAN proposes another pricing model for essential drugs by Khomba Singh&#039;
$metaKeywords = &#039;Health,medicines&#039;
$metaDesc = &#039;



A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;





The proposal of the All India Drug Action Network (AIDAN) is...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | AIDAN proposes another pricing model for essential drugs by Khomba Singh | Im4change.org</title>
    <meta name="description" content="



A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;





The proposal of the All India Drug Action Network (AIDAN) is..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>AIDAN proposes another pricing model for essential drugs by Khomba Singh</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify"><br /></div><div style="text-align: justify">A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The group had earlier proposed another pricing formula but it was rejected by the industry. &quot;We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry,&quot; said Mira Shiva, founder co-ordinator of AIDAN.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &quot;impractical and non-transparent&quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The group had earlier proposed another pricing formula but it was rejected by the industry. &quot;We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry,&quot; said Mira Shiva, founder co-ordinator of AIDAN.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &quot;impractical and non-transparent&quot;.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6cebcedce5-trace').style.display = (document.getElementById('cakeErr67f6cebcedce5-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f6cebcedce5-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6cebcedce5-code').style.display = (document.getElementById('cakeErr67f6cebcedce5-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6cebcedce5-context').style.display = (document.getElementById('cakeErr67f6cebcedce5-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f6cebcedce5-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f6cebcedce5-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 13535,
		&#039;title&#039; =&gt; &#039;AIDAN proposes another pricing model for essential drugs by Khomba Singh&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 13 March, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/aidan-proposes-another-pricing-model-for-essential-drugs/articleshow/12&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 13657,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 13535,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | AIDAN proposes another pricing model for essential drugs by Khomba Singh&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;



A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;





The proposal of the All India Drug Action Network (AIDAN) is...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 13535,
	&#039;title&#039; =&gt; &#039;AIDAN proposes another pricing model for essential drugs by Khomba Singh&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 13 March, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/aidan-proposes-another-pricing-model-for-essential-drugs/articleshow/12&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 13657,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 13535
$metaTitle = &#039;LATEST NEWS UPDATES | AIDAN proposes another pricing model for essential drugs by Khomba Singh&#039;
$metaKeywords = &#039;Health,medicines&#039;
$metaDesc = &#039;



A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;





The proposal of the All India Drug Action Network (AIDAN) is...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The group had earlier proposed another pricing formula but it was rejected by the industry. &amp;quot;We have proposed this alternate model, if our earlier recommendation or the health ministry&#039;s proposals are not acceptable to industry,&amp;quot; said Mira Shiva, founder co-ordinator of AIDAN.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &amp;quot;impractical and non-transparent&amp;quot;.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Sales of these drugs account for about three-fifths of the country&#039;s Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The DoP&#039;s draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government&#039;s bulk procurement price.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | AIDAN proposes another pricing model for essential drugs by Khomba Singh | Im4change.org</title>
    <meta name="description" content="



A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;





The proposal of the All India Drug Action Network (AIDAN) is..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>AIDAN proposes another pricing model for essential drugs by Khomba Singh</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify"><br /></div><div style="text-align: justify">A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The group had earlier proposed another pricing formula but it was rejected by the industry. &quot;We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry,&quot; said Mira Shiva, founder co-ordinator of AIDAN.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &quot;impractical and non-transparent&quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The group had earlier proposed another pricing formula but it was rejected by the industry. &quot;We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry,&quot; said Mira Shiva, founder co-ordinator of AIDAN.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &quot;impractical and non-transparent&quot;.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 13535,
		'title' => 'AIDAN proposes another pricing model for essential drugs by Khomba Singh',
		'subheading' => '',
		'description' => '<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The group had earlier proposed another pricing formula but it was rejected by the industry. &quot;We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry,&quot; said Mira Shiva, founder co-ordinator of AIDAN.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &quot;impractical and non-transparent&quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The group had earlier proposed another pricing formula but it was rejected by the industry. &quot;We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry,&quot; said Mira Shiva, founder co-ordinator of AIDAN.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &quot;impractical and non-transparent&quot;.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price.
</div>',
		'credit_writer' => 'The Economic Times, 13 March, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/aidan-proposes-another-pricing-model-for-essential-drugs/articleshow/12',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 13657,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 13535,
	'metaTitle' => 'LATEST NEWS UPDATES | AIDAN proposes another pricing model for essential drugs by Khomba Singh',
	'metaKeywords' => 'Health,medicines',
	'metaDesc' => '



A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;





The proposal of the All India Drug Action Network (AIDAN) is...',
	'disp' => '<div style="text-align: justify"><br /></div><div style="text-align: justify">A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The group had earlier proposed another pricing formula but it was rejected by the industry. &quot;We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry,&quot; said Mira Shiva, founder co-ordinator of AIDAN.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &quot;impractical and non-transparent&quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The group had earlier proposed another pricing formula but it was rejected by the industry. &quot;We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry,&quot; said Mira Shiva, founder co-ordinator of AIDAN.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &quot;impractical and non-transparent&quot;.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price.</div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 13535,
	'title' => 'AIDAN proposes another pricing model for essential drugs by Khomba Singh',
	'subheading' => '',
	'description' => '<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The group had earlier proposed another pricing formula but it was rejected by the industry. &quot;We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry,&quot; said Mira Shiva, founder co-ordinator of AIDAN.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &quot;impractical and non-transparent&quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The group had earlier proposed another pricing formula but it was rejected by the industry. &quot;We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry,&quot; said Mira Shiva, founder co-ordinator of AIDAN.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &quot;impractical and non-transparent&quot;.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&nbsp;
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price.
</div>',
	'credit_writer' => 'The Economic Times, 13 March, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/aidan-proposes-another-pricing-model-for-essential-drugs/articleshow/12',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'aidan-proposes-another-pricing-model-for-essential-drugs-by-khomba-singh-13657',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 13657,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 13535
$metaTitle = 'LATEST NEWS UPDATES | AIDAN proposes another pricing model for essential drugs by Khomba Singh'
$metaKeywords = 'Health,medicines'
$metaDesc = '



A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;





The proposal of the All India Drug Action Network (AIDAN) is...'
$disp = '<div style="text-align: justify"><br /></div><div style="text-align: justify">A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The group had earlier proposed another pricing formula but it was rejected by the industry. &quot;We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry,&quot; said Mira Shiva, founder co-ordinator of AIDAN.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &quot;impractical and non-transparent&quot;. In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The group had earlier proposed another pricing formula but it was rejected by the industry. &quot;We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry,&quot; said Mira Shiva, founder co-ordinator of AIDAN.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it &quot;impractical and non-transparent&quot;.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.&nbsp;</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price.</div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

AIDAN proposes another pricing model for essential drugs by Khomba Singh

A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.  The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.  The group had earlier proposed another pricing formula but it was rejected by the industry. "We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry," said Mira Shiva, founder co-ordinator of AIDAN.  The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs.  In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs. The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday.  The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it "impractical and non-transparent". In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.  Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.  The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price. I A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.  The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make medicines cheaper than the formula suggested by the DoP.  The group had earlier proposed another pricing formula but it was rejected by the industry. "We have proposed this alternate model, if our earlier recommendation or the health ministry's proposals are not acceptable to industry," said Mira Shiva, founder co-ordinator of AIDAN.  The government, which is consulting all stakeholders before framing a new drug pricing policy, has received several suggestions to bring down the cost of essential drugs. In 2003, the Supreme Court disbanded the Pharma Policy 2002-which proposed to bring down the number of bulk drugs under price control from 74 to 38-saying it would dilute price control regulation. It also asked the government to regulate prices of all essential drugs.  The matter is being finalised under the direction of the Supreme Court and the case comes up for hearing on Tuesday. The NGO had earlier suggested that the government should continue with the existing mechanism of fixing prices based on the cost of production. But this was rejected by industry, which termed it "impractical and non-transparent".  In October, the DoP had floated a draft National Pharmaceutical Pricing Policy that proposes to cap the prices of 348 essential medicines and their formulations at the average price of the three best-selling brands.  Sales of these drugs account for about three-fifths of the country's Rs 60,000-crore pharmaceutical market. In its initial feedback, AIDAN had said that the DoP proposal would increase prices of medicines since the best-selling brands are invariably the costlier ones, a view shared by experts, the health ministry and the WHO.  The DoP's draft policy has also been rejected by health ministry, which says the pricing should be based on either the average price of the three cheapest brands or the government's bulk procurement price.